Urinary Tract Infection

Clinical Snapshot

Urinary tract infection (UTI) is classified by clinical presentation, not by patient demographics. Uncomplicated UTI is an infection confined to the bladder (cystitis) without systemic features — this now includes men, since sex alone no longer defines complexity. Complicated UTI is defined by systemic signs suggesting infection beyond the bladder: fever, flank pain, bacteremia, sepsis, or association with an indwelling urinary device. Diabetes, older age, or male sex alone do not automatically make a UTI "complicated" under the current classification.^[1] Escherichia coli is the dominant pathogen across all UTI syndromes. Treatment duration for complicated UTI and pyelonephritis is now substantially shorter than older guidance — 5-7 days, not 10-14 — when the patient is responding to effective therapy.^[1]

Recognize the Condition

The UTI clinical syndromes

Uncomplicated UTI (cystitis)

Internal dysuria (burning inside the urethra — a burning sensation on the outside is more consistent with vaginitis).
Urinary frequency, urgency, and suprapubic discomfort.
No fever, flank pain, or systemic symptoms.

Complicated UTI / acute pyelonephritis

Fever, flank pain, costovertebral angle tenderness.
Nausea and vomiting may be present.
May occur with or without lower urinary tract symptoms — occult renal infection can present with only cystitis-type symptoms.
Bacteremic infection is more frequent in diabetic patients and in patients over 65.

Acute bacterial prostatitis

Acute onset chills, fever, perineal and low back pain, irritative and obstructive voiding symptoms.
Prostate is tender, swollen, indurated, and warm on exam.
Do not perform prostatic massage — it may cause bacteremia.

Chronic bacterial prostatitis

A common cause of recurrent UTI in older men. Presents as intermittent cystitis-like infection with a history of recurrent UTIs; prostate exam is usually normal. Chronic pelvic pain symptoms without microbiologic documentation of infection are not attributable to bacterial infection and do not respond to antimicrobial therapy versus placebo.

Asymptomatic bacteriuria

Bacteria present in urine (≥10⁸ cfu/L) without any symptoms of infection. This is a laboratory finding, not a diagnosis requiring treatment in most patients.

Infecting organisms by syndrome

Knowing the expected organism by syndrome guides empiric selection before culture results return:

Syndrome	Typical organisms
Acute uncomplicated cystitis	Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis
Acute nonobstructive pyelonephritis	E. coli, K. pneumoniae, P. mirabilis
Complicated UTI (structural/functional abnormality, indwelling catheter, virtually all UTIs in men)	E. coli, P. mirabilis, Enterococcus faecalis, Pseudomonas aeruginosa, Providencia stuartii, Citrobacter spp., Enterobacter spp., Serratia spp., group B streptococcus
Acute bacterial prostatitis	E. coli, other Enterobacteriaceae, P. aeruginosa, Staphylococcus aureus
Chronic bacterial prostatitis	E. coli, Klebsiella spp., P. aeruginosa, Proteus spp.
Asymptomatic bacteriuria	E. coli, P. mirabilis, group B streptococcus, coagulase-negative staphylococcus

Isolation of another gram-positive organism (e.g., group B streptococcus, coagulase-negative staphylococcus) in an uncomplicated-cystitis specimen should be considered contamination rather than the causative organism.

Risk Factors

Sexual intercourse and use of spermicide or a diaphragm.
Genetic predisposition to recurrent UTI.
Postmenopausal status with vaginal atrophy.
Indwelling catheter or recent instrumentation.
Structural or functional genitourinary abnormality.
Diabetes and immunosuppression (risk factors for severity, not automatic classifiers of "complicated" disease).
Pregnancy.

Red Flags & Refer

Refer for urgent/emergency assessment for any of the following:

Sepsis or hemodynamic instability.
Inability to tolerate oral intake or medications.
Severe flank pain with high fever.
Suspected obstruction (e.g., stone with infection) — a urologic emergency.
Pregnancy with suspected pyelonephritis.
Acute bacterial prostatitis.
Failure of outpatient therapy with clinical deterioration.
Men presenting with any febrile UTI — warrants careful evaluation for prostatitis or a structural cause.

Assessment & Diagnosis

When to culture

Direct ruleFor uncomplicated cystitis, clinical diagnosis is reliable for most episodes and routine culture is generally not recommended. Culture is appropriate for: treatment failure, early (<1 month) recurrence, diagnostic uncertainty, or pregnancy. For all complicated UTI, pyelonephritis, and prostatitis, always obtain a urine culture before starting antimicrobial therapy and tailor therapy to the result.^[1]

Diagnostic thresholds

Uncomplicated cystitis: any quantitative count of a gram-negative organism or S. saprophyticus in a voided specimen with pyuria supports the diagnosis.
Pyelonephritis: ≥10⁷ cfu/L (10⁴ cfu/mL) in a voided specimen.
Complicated UTI: ≥10⁸ cfu/L (10⁵ cfu/mL) voided, or any quantitative count from an in-and-out catheterized specimen.
Asymptomatic bacteriuria: ≥10⁸ cfu/L in 2 consecutive specimens in women, or 1 specimen in men — and only relevant to test for in pregnancy or before an invasive urologic procedure with expected mucosal bleeding.

Do not over-test

Growing evidence supports relying on clinical judgment rather than reflexive microbial detection — a positive culture in the absence of symptoms is not an indication to treat.^[2]

Treatment Targets

Relieve symptoms of acute infection.
Prevent complications of untreated infection (pyelonephritis, bacteremia).
Prevent recurrent infection.
Prevent pyelonephritis and adverse pregnancy outcomes when the patient is pregnant.
Avoid unnecessary antimicrobial exposure — do not treat asymptomatic bacteriuria outside pregnancy or pre-procedure indications.

Choose Initial Treatment

Direct treatment rule

Uncomplicated cystitis (bladder-confined, no systemic features — women or men)

1st line nitrofurantoin 5 days, OR sulfamethoxazole/trimethoprim 3 days (only where local E. coli resistance is under 20%), OR trimethoprim alone 3 days, OR fosfomycin tromethamine as a single 3 g dose.^[3]

2nd line use when a 1st-line agent is contraindicated (e.g., CrCl < 30 mL/min for nitrofurantoin, sulfa allergy for SMX/TMP, local resistance ≥ 20%) or not tolerated: cephalexin 7 days, OR ciprofloxacin/levofloxacin 3 days.

Reserve fluoroquinolones for patients with no remaining 1st- or 2nd-line option — their risks outweigh their benefit in uncomplicated cystitis.^[4]

Complicated UTI / mild-to-moderate pyelonephritis (hemodynamically stable, tolerating oral intake)

1st line ciprofloxacin or levofloxacin, nitrofurantoin (cystitis-pattern complicated UTI only, not pyelonephritis), sulfamethoxazole/trimethoprim, trimethoprim, or a cephalosporin.

Duration is 5-7 days for a fluoroquinolone or 7 days for a non-fluoroquinolone agent, once the patient is clinically improving on effective therapy.^[1]

Severe/septic complicated UTI or pyelonephritis — move here when the patient is septic, hemodynamically unstable, vomiting, or cannot tolerate oral intake

1st line (IV) a 3rd/4th-generation cephalosporin, piperacillin/tazobactam, a carbapenem, or a fluoroquinolone, selected using a 4-step process: (1) assess sepsis severity, (2) review any urine culture from the past 3-6 months, (3) check patient-specific allergy/interaction factors, (4) consult the local antibiogram if septic.

Switch to oral therapy once the patient is clinically improving, tolerating oral intake, and an effective oral option exists — regardless of whether bacteremia was present; total duration is still only 7 days, even for bacteremic infection.^[1]

Acute bacterial prostatitis

1st line (IV) aminoglycoside ± ampicillin (add ampicillin if Enterococcus is a concern).

Step down to oral ciprofloxacin/levofloxacin or sulfamethoxazole/trimethoprim once improving, to complete 4 weeks total.

Asymptomatic bacteriuria

Do not treat except in pregnancy or immediately before a urologic procedure expected to cause mucosal bleeding.^[5]

Non-Pharmacologic Treatment

Symptomatic patients should still be offered antimicrobial therapy — NSAID monotherapy instead of antibiotics is associated with a higher rate of complications, including pyelonephritis, and should not be used.^[3]
Increased water intake is a reasonable, low-risk adjunct for women drinking less than 1.5 L/day, though the effect on recurrence is modest.^[2]
Avoid spermicide-containing products in patients with recurrent UTI — they are an established risk factor.
Vaginal estrogen therapy is recommended (not just an option) for peri- and postmenopausal women with recurrent UTI when there is no contraindication.^[2]

Natural health products — what the current evidence actually supports

Cranberry

Should be offered as a prevention option for women with recurrent UTI — this is a genuine change from older guidance that dismissed cranberry outright.^[2]

D-mannose

Not effective as a stand-alone prevention strategy — do not rely on it alone.^[2]

Methenamine hippurate

May be offered as a non-antibiotic prophylaxis alternative.^[2]

Probiotics

No evidence supports lactobacillus-containing probiotic products for UTI prevention or treatment.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Nitrofurantoin Preferred	Uncomplicated cystitis, 1st line	100 mg PO BID for 5 days (monohydrate/macrocrystals)	GI upset, rare pulmonary/hepatic toxicity with prolonged use	Contraindicated if CrCl under 30 mL/min. May be used regardless of prior antibiotic exposure, but avoid near term in pregnancy.
Sulfamethoxazole/Trimethoprim Preferred	Uncomplicated cystitis, 1st line (if local resistance under 20%)	1 DS tablet PO BID for 3 days	Rash, hyperkalemia, cytopenias	Avoid first trimester and last 6 weeks of pregnancy.
Trimethoprim Preferred	Uncomplicated cystitis, 1st line, sulfa allergy alternative	100 mg PO BID for 3 days	Rash, hyperkalemia especially in elderly/renal impairment	Use when sulfa allergy precludes SMX/TMP.
Fosfomycin tromethamine Preferred	Uncomplicated cystitis, 1st line, single-dose option	One 3 g sachet PO x 1 dose	Diarrhea, headache, nausea, vaginitis	No cross-resistance with other classes. Slightly less effective than the alternatives but useful for adherence.
Cephalexin Alternative	Uncomplicated cystitis, 2nd line	500 mg PO Q6H for 7 days	GI upset, hypersensitivity	Less well studied than 1st-line agents; associated with more vulvovaginal candidiasis.
Ciprofloxacin Alternative	Complicated UTI/pyelonephritis, and cystitis without an alternative option	500 mg PO BID for 5-7 days (cUTI); 3 days for uncomplicated cystitis if needed	Tendinopathy, neuropathy, CNS/QT effects	Reserve for cases without another suitable option in uncomplicated cystitis.<cite data-reference-id="81b1ad75-4bdb-4b07-a7cc-363efd0b3ec8"></cite>
Ceftriaxone Preferred	Empiric IV therapy for complicated UTI/pyelonephritis; preferred in pregnancy	1 g IV/IM once daily	Hypersensitivity, GI effects	Step down to oral once improving; total course 7 days.
Piperacillin/tazobactam Special situation	Severe/septic complicated UTI, empiric broad coverage	3.375 g IV Q6H	Hypersensitivity, GI effects, cytopenias	Select per the 4-step severity/risk/allergy/antibiogram process.
Methenamine hippurate Special situation	Recurrent-UTI prevention, non-antibiotic alternative	1 g PO BID (product-dependent)	GI upset; avoid in significant renal impairment	2025 AUA guideline: may be offered as a non-antibiotic prophylaxis option.

Special Populations

Pregnancy

Screen for asymptomatic bacteriuria at 12-16 weeks and treat if confirmed on 2 consecutive cultures — untreated bacteriuria in pregnancy can progress to pyelonephritis and cause adverse fetal outcomes.^[6] Follow up with a urine culture 1-2 weeks after completing therapy, then monthly until delivery.

Preferred in pregnancy

Amoxicillin (if susceptible), amoxicillin/clavulanate, cephalexin, fosfomycin (if susceptible). Ceftriaxone is preferred empiric therapy for pyelonephritis in pregnancy, stepped down to oral once stable.

Avoid in pregnancy

Nitrofurantoin near term (hemolytic anemia risk, especially with G6PD deficiency — rare but real). Trimethoprim and SMX/TMP in the first trimester (antifolate teratogenicity) and SMX/TMP in the last 6 weeks (neonatal hyperbilirubinemia). Fluoroquinolones throughout pregnancy.

Breastfeeding

Fluoroquinolones, nitrofurantoin, and SMX/TMP are all considered compatible with breastfeeding by the American Academy of Pediatrics. Amoxicillin and cephalosporins are also compatible.

Men

A UTI in a man is uncomplicated only if it is bladder-confined without systemic features; febrile UTI in a man should prompt evaluation for prostatitis or a structural genitourinary cause.^[1]

Monitoring & Follow-Up

Uncomplicated cystitis should resolve within a few days of starting therapy; about half of symptomatic patients become symptom-free within 7 days even without antibiotics, but antibiotics reduce symptom burden and duration compared with NSAID monotherapy and should still be offered. Obtain a urine culture if recurrence occurs within 1 month of treatment. For pyelonephritis/complicated UTI, expect clinical improvement (fever resolution, hemodynamic stability) within 48-72 hours — this is the trigger for IV-to-oral switch, not a fixed number of IV days. For pregnancy, follow up with a culture 1-2 weeks after treatment and then monthly until delivery.

Treatment Failure / Next Step

Confirm the diagnosis — reconsider vaginitis, urethritis, or interstitial cystitis if symptoms don't fit typical cystitis.
Obtain a urine culture if not already done, and review susceptibility.
Retreat with a different antimicrobial class if the initial agent was anything other than nitrofurantoin (nitrofurantoin may be reused regardless of prior therapy).
For recurrence within 1 month, this represents relapse (same organism, incomplete eradication) — investigate for a structural cause or occult renal/prostatic focus rather than simply repeating the same short course.
For men or anyone with recurrent same-organism infection, evaluate for chronic prostatitis or a structural abnormality.

Common Errors to Avoid

Screening or treating asymptomatic bacteriuria in healthy, nonpregnant patients.
Classifying every UTI in a man or every UTI in a diabetic patient as "complicated" by default — classification depends on systemic features, not demographics.^[1]
Using a 10-14 day course for pyelonephritis/complicated UTI when the patient is responding — the current standard is 5-7 days.
Reaching for a fluoroquinolone as first-line therapy for uncomplicated cystitis.
Treating chronic pelvic pain in men as prostatitis without microbiologic confirmation.
Recommending cranberry with the outdated "no evidence" framing — the 2025 AUA guideline now supports offering it (Grade B).
Relying on D-mannose alone as an effective preventive strategy.
Performing prostatic massage in suspected acute bacterial prostatitis.

Clinical Decision Algorithm

Algorithm A — Classify and treat by presentation

Urinary symptoms: dysuria, frequency, urgency, suprapubic discomfort ± fever/flank pain

Assess for systemic features: fever, flank pain, bacteremia, sepsis, or indwelling device

Bladder-confined only, no systemic features (any sex)

Uncomplicated cystitis: clinical diagnosis, routine culture generally not needed

Nitrofurantoin x5d, SMX/TMP x3d, trimethoprim x3d, or fosfomycin x1 dose

Systemic features present

Complicated UTI / pyelonephritis: always obtain urine culture before starting therapy

Hemodynamically stable, tolerating oral intake

Oral fluoroquinolone (5-7d) or non-fluoroquinolone agent (7d)

Septic or unable to tolerate oral intake

IV therapy selected via 4-step process (severity, recent culture, allergy/interaction, antibiogram); switch to oral once improving — total course still 7 days

Algorithm B — Recurrent UTI prevention (≥2 episodes/6 months or ≥3/12 months)

Recurrent uncomplicated cystitis confirmed

Related to intercourse

Post-coital single-dose prophylaxis using a 1st- or 2nd-line agent

Frequent, not clearly related to intercourse

Continuous low-dose prophylaxis: nitrofurantoin 50-100 mg daily or SMX/TMP 200/40 mg daily, 6-12 months, then reassess

Peri-/postmenopausal

Add vaginal estrogen if no contraindication — recommended, not just optional

Consider cranberry (Grade B, should offer) or methenamine hippurate (Grade C, may offer) as non-antibiotic adjuncts; D-mannose alone is not recommended

Alternative: patient-initiated self-start therapy with a first-line agent at symptom onset

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Nitrofuran derivatives (uncomplicated cystitis, 1st line)

Drug	Dosage	Adverse effects	Comments
Nitrofurantoin monohydrate/macrocrystals	Adults, treatment: 100 mg PO Q12H for 5 days Children, treatment: 5-7 mg/kg/day divided QID PO per current product monograph Recurrence/prophylaxis (adults): 50-100 mg PO once daily, continuous, for 6-12 months, then reassess	Headache, nausea, flatulence; rare pulmonary/hepatic toxicity with long-term use	Better tolerated than the plain macrocrystal formulation. Contraindicated if CrCl under 30 mL/min.

Phosphonic acid derivatives (uncomplicated cystitis, 1st line)

Drug	Dosage	Adverse effects	Comments
Fosfomycin tromethamine	Adults, treatment: One 3 g sachet PO x 1 dose Children: Not established for routine pediatric UTI — specialist-directed only	Diarrhea, headache, nausea, vaginitis	No cross-resistance with other antimicrobial classes.

Folate antagonists / sulfonamide combinations (uncomplicated cystitis, 1st line)

Drug	Dosage	Adverse effects	Comments
Trimethoprim	Adults, treatment: 100 mg PO Q12H for 3 days Children, treatment: 8-12 mg/kg/day divided Q12H PO	Rash, pruritus, hyperkalemia (elderly/renal impairment)	Use in sulfa-allergic patients instead of SMX/TMP.
Sulfamethoxazole/trimethoprim	Adults, treatment: 800/160 mg (1 DS tablet) PO Q12H for 3 days Infants (2 months+), children, adolescents, treatment: 8-12 mg/kg/day (TMP component) divided Q12H PO Recurrence/prophylaxis (adults): 200/40 mg PO once daily, continuous, for 6-12 months, then reassess	Rash, hyperkalemia, cytopenias, false increase in serum creatinine	Only if local E. coli resistance is under 20%. Increases phenytoin levels and INR with warfarin.

Cephalosporins (2nd line, or IV empiric for complicated UTI)

Drug	Dosage	Adverse effects	Comments
Cephalexin	Adults: 500 mg PO Q6H for 7 days Children: 25-50 mg/kg/day divided Q6H PO	GI upset, hypersensitivity	2nd-line oral option for uncomplicated cystitis.
Cefixime	Adults: 400 mg PO once daily for 7-10 days Children: 8 mg/kg/day PO once daily or divided Q12H	GI upset, hypersensitivity	Oral option for mild-to-moderate complicated UTI.
Cefazolin	Adults: 1 g IV Q8H Children: 50-100 mg/kg/day divided Q8H IV (max 6000 mg/day)	Hypersensitivity, GI effects	Parenteral option for complicated UTI/pyelonephritis.
Cefotaxime	Adults: 1 g IV Q8H Children: Weight-based per current product monograph	Hypersensitivity, GI effects	Safe in hepatobiliary disease.
Ceftazidime	Adults: 1 g IV Q8H Children: Weight-based per current product monograph	Hypersensitivity, GI effects	Broader Gram-negative coverage including Pseudomonas.
Ceftriaxone	Adults: 1 g IV/IM once daily Children: 50-75 mg/kg IV once daily (max 1000 mg/day)	Hypersensitivity, GI effects	Preferred empiric IV therapy for pyelonephritis in pregnancy. Do not co-administer with calcium-containing IV solutions.

Fluoroquinolones (reserve for cases without an alternative in uncomplicated cystitis)

Health Canada has issued a safety warning restricting routine fluoroquinolone use given tendinopathy, neuropathy, and CNS risks.<cite data-reference-id="81b1ad75-4bdb-4b07-a7cc-363efd0b3ec8"></cite>

Drug	Dosage	Adverse effects	Comments
Ciprofloxacin	Adults, uncomplicated cystitis: 250-500 mg PO Q12H for 3 days Adults, complicated UTI/pyelonephritis: 500 mg PO BID for 5-7 days Children: Generally avoided — reserve for specialist-directed use only	Tendinopathy, peripheral neuropathy, CNS effects, QT prolongation, photosensitivity	Reserve for cases without alternative treatment options.

Penicillins

Drug	Dosage	Adverse effects	Comments
Amoxicillin	Adults: 500 mg PO Q8H Children: Weight-based per current product monograph	Hypersensitivity, GI effects	Not recommended for empiric therapy — reserve for known-susceptible organisms.
Amoxicillin/clavulanate	Adults: 500 mg PO Q8H or 875 mg PO Q12H Children: 40 mg/kg/day (amoxicillin component) divided Q8H PO (max 1750 mg/day)	Hypersensitivity, GI effects (10-25% incidence)	3rd-line for uncomplicated cystitis when alternatives cannot be used; preferred option in pregnancy.
Piperacillin/tazobactam	Adults: 3.375 g IV Q6H Children: 240-300 mg/kg/day (piperacillin component) divided Q6-8H IV (max 16 g/day)	Hypersensitivity, GI effects, cytopenias	Empiric option for severe/septic complicated UTI.

Aminoglycosides (severe pyelonephritis/prostatitis, initial parenteral therapy)

Switch to oral once signs and symptoms have settled, typically 72-96 hours; short duration keeps oto/nephrotoxicity risk low. Dosing is weight-based and applies across adult and pediatric patients.

Drug	Dosage	Adverse effects	Comments
Gentamicin	Adults and children: 3-5 mg/kg/day IV	Nephrotoxicity (usually reversible), ototoxicity (may be irreversible)	Increased toxicity with loop diuretics and other nephrotoxic drugs.
Tobramycin	Adults and children: 3-5 mg/kg/day IV	Nephrotoxicity, ototoxicity	Interchangeable with gentamicin; selection by susceptibility/cost.
Amikacin	Adults and children: 15-20 mg/kg/day IV	Nephrotoxicity, ototoxicity	Reserve for resistant organisms.

Carbapenems (ESBL-producing organisms, severe complicated UTI)

Drug	Dosage	Adverse effects	Comments
Ertapenem	Adults (13 years+): 1 g IV Q24H Children 3 months-12 years: 15 mg/kg IV Q12H (max 500 mg/dose)	Diarrhea, headache, seizures (rare)	Not active against Pseudomonas aeruginosa. Decreases valproic acid levels.
Meropenem	Adults: 0.5-1 g IV Q8H Children: Weight-based per current pediatric protocol; consult pediatric infectious diseases	Diarrhea, headache, seizures (rare)	Active against Pseudomonas aeruginosa, unlike ertapenem.

References

IDSA 2025 Guideline Update on Complicated Urinary Tract Infections — Infectious Diseases Society of America. First major update since 2010
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025 Amendment) — American Urological Association / Canadian Urological Association / SUFU. 2025 amendment, released September 2025
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases — Clinical Infectious Diseases (Gupta K, Hooton TM, Naber KG, et al.). Clin Infect Dis 2011;52(5):e103-e120
Fluoroquinolones – Risk of disabling and potentially permanent serious side effects — Health Canada. Health Canada Recalls and Safety Alerts, January 2017
Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America — Clinical Infectious Diseases (Nicolle LE, Gupta K, Bradley SF, et al.). Clin Infect Dis 2019;68(10):e83-e110
Urinary tract infections during pregnancy — Annals of Pharmacotherapy (Le J, Briggs GG, McKeown A, et al.). Ann Pharmacother 2004;38(10):1692-1701

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.